Matthew Herper says: There were plenty of reasons to be skeptical, so this doesn't neccesarily dent the amyloid hypothesis. Still a disappointment. Myriad's diagnostic test business is cushioning the blow. Click on the article to read a nice take from Adam Feuerstein over at TheStreet.com. |
View the Top Clips from June 30, 2008
Embed This Clip In Your Site...
|
||||||||||
|
|
|||||||||||